SRX Global Inc. Announces Additional Private Placement Closing for $3.47M

What Happened SRX Global Inc. (f/k/a SRx Health Solutions) filed an 8‑K reporting an Additional Closing under the March 16, 2026 Securities Purchase Agreement. On July 27, 2026, the company issued and sold 4,340 shares of its Series B convertible preferred stock and 284,156 warrants to purchase common stock for aggregate cash proceeds of approximately $3.472 million. This additional closing, together with the initial March 16, 2026 closing, brings the total issued under the agreement to 10,000 Series B shares for combined proceeds of about $8.0 million. The July warrant count reflects the company’s 60‑for‑1 reverse stock split that took effect July 2, 2026.

Key Details

• Initial closing (March 16, 2026): 5,660 Series B shares and 22,237,666 warrants for ~$4.528 million (cash proceeds).
• Additional closing (July 27, 2026): 4,340 Series B shares and 284,156 warrants for ~$3.472 million (cash proceeds).
• Aggregate under the Securities Purchase Agreement: 10,000 Series B shares and total proceeds of approximately $8.0 million.
• Securities were issued in a private placement relying on Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D to accredited investors; the securities are unregistered and not being publicly offered.

Why It Matters The company raised approximately $3.47 million in this additional financing and roughly $8.0 million in total under the agreement, providing immediate cash to the business. Investors should note these are convertible preferred shares and warrants, which can increase the company’s outstanding common shares if converted or exercised and therefore may dilute existing shareholders. The issuance was made in a private placement to accredited investors under registration exemptions, meaning the securities are not registered for public resale.